These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1947759)

  • 21. NCI-EORTC 2nd International Meeting on Cancer Diagnosis: From Discovery to Clinical Practice. June 26-29, 2002. Washington, DC, USA. Abstracts.
    Int J Biol Markers; 2002; 17 Suppl 2():S1-63. PubMed ID: 12185997
    [No Abstract]   [Full Text] [Related]  

  • 22. [The role of cytokines as tumor markers].
    Mroczko B; Szmitkowski M
    Pol Arch Med Wewn; 1997 Feb; 97(2):170-6. PubMed ID: 9312766
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumor markers in infancy and childhood.
    Ricafort R
    Pediatr Rev; 2011 Jul; 32(7):306-8. PubMed ID: 21724907
    [No Abstract]   [Full Text] [Related]  

  • 24. Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen - a prospective study.
    Bhattacharjya S; Aggarwal R; Davidson BR
    Br J Cancer; 2006 Jul; 95(1):21-6. PubMed ID: 16804525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Markers in the Diagnosis and Treatment of Cancer.
    Gokden M; Ariza A; Arnaoutakis K
    Biomed Res Int; 2015; 2015():105217. PubMed ID: 26451364
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical usefulness of tumour markers.
    Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
    Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.
    Tuzun Y; Yilmaz S; Dursun M; Canoruc F; Celik Y; Cil T; Boyraz T
    J Int Med Res; 2009; 37(1):87-95. PubMed ID: 19215677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum tumour markers in clinical practice. Some general aspects.
    Kvinnsland S
    Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic mirnas as potential biomarkers for malignancy.
    Healy NA; Heneghan HM; Miller N; Osborne CK; Schiff R; Kerin MJ
    Int J Cancer; 2012 Nov; 131(10):2215-22. PubMed ID: 22618667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 1st International Conference on Trace Elements, Free Radicals, Tumour Markers, Chromosomal Analysis, and Cytokines in Clinical Medicine and Biochemistry (TFTCC). Kuwait City, Kuwait, 20-23 March 1995. Proceedings and abstracts.
    Nutrition; 1995; 11(5 Suppl):487-724. PubMed ID: 8845592
    [No Abstract]   [Full Text] [Related]  

  • 31. Screening with tumor markers: critical issues.
    Roulston JE
    Mol Biotechnol; 2002 Feb; 20(2):153-62. PubMed ID: 11876472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Malignant diseases in children--diagnosis and evaluation of the prognosis with tumor markers and special laboratory tests].
    Göbel U
    Kinderkrankenschwester; 1997 Jun; 16(6):219-25. PubMed ID: 9248423
    [No Abstract]   [Full Text] [Related]  

  • 33. Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 3).
    Gion M; Trevisiol C; Rutjes AWS; Rainato G; Fabricio ASC
    Int J Biol Markers; 2017 May; 32(2):e147-e181. PubMed ID: 28475208
    [No Abstract]   [Full Text] [Related]  

  • 34. Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 2).
    Gion M; Trevisiol C; Rutjes AWS; Rainato G; Fabricio ASC
    Int J Biol Markers; 2017 Mar; 32(1):e1-e52. PubMed ID: 28255982
    [No Abstract]   [Full Text] [Related]  

  • 35. [The future of molecular markers in cancer: towards a tailored treatment].
    Gascón P
    Med Clin (Barc); 2009 Apr; 132(14):549-50. PubMed ID: 19368936
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical Relevance of Intra-Tumour Heterogeneity.
    Borisch B; Stanta G
    Pathobiology; 2018; 85(1-2):5-6. PubMed ID: 29642072
    [No Abstract]   [Full Text] [Related]  

  • 37. Diagnostic technologies for circulating tumour cells and exosomes.
    Shao H; Chung J; Issadore D
    Biosci Rep; 2015 Nov; 36(1):e00292. PubMed ID: 26604322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Glycolipid markers in tumor cells used in immunologic and immunohistologic diagnosis of tumors. I. Factors affecting the occurrence of glycolipid tumor antigens (review)].
    Smíd F
    Cesk Patol; 1991 Jun; 27(3-4):116-23. PubMed ID: 1913919
    [No Abstract]   [Full Text] [Related]  

  • 39. [Gender differences in the use of tumour markers].
    Moreno-Campoy EE; Mérida-De la Torre FJ; Martos-Crespo F; Plebani M
    Rev Calid Asist; 2015; 30(6):327-34. PubMed ID: 26410238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of tumour markers in cancer diagnosis and treatment.
    Higgins C
    Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.